Drug Companies
Innovative therapies with overseas approval, clinical evidence, or a defined China-entry question.
CHINA HEALTHCARE MARKET ENTRY PATHWAYS
Find Your China Entry PathwayBefore Full Registration
Source-basedPlain-English analysis grounded in official and publicly available policy sources.
Healthcare focusedBuilt around drugs, devices, diagnostics, digital health, and clinical-use pathways.
Partner readyDesigned to support matching with China-based clinical, commercial, and industrial resources.
WHO THIS HELPS
Who This Is For
AsterNexis Advisory is designed for overseas healthcare innovators deciding whether China’s special access pathways are relevant before committing major resources to full market entry.
Medical Device Companies
Device teams assessing controlled clinical use, import scenarios, hospital demand, or partner readiness.
Diagnostics Companies
Diagnostic products evaluating evidence needs, hospital fit, and China-based commercialization paths.
Digital Health and AI Health
Software, digital therapeutic, and AI-enabled health companies exploring pilot-region opportunities.
ASSESSMENT QUESTIONS
Turn Policy Options Into a Practical Entry Plan
AsterNexis Advisory helps overseas healthcare teams identify the right route, evidence requirements, partners, and next steps for entering China.
Is my product a fit?
Whether Hainan, GBA, Beijing, or another pilot route may be relevant.
What is the access model?
Clinical use, real-world data, local partner, park landing, or commercial strategy.
What are the constraints?
Eligibility, institutional application, product status, evidence, import rules, and compliance.
Who should I talk to?
Hospitals, parks, distributors, investors, or government-facing platforms.
What should I prepare?
Product profile, approval status, clinical evidence, regulatory history, and China objectives.
ASSESSMENT PROCESS
How the Assessment Works
POLICY GUIDANCE
Evidence-Based Pathway Assessment
Special Access & Market Entry
Lecheng may provide controlled access for selected clinically urgent imported drugs and devices, subject to institutional application, official procedures, approval, and traceability requirements.
Real-World Evidence & Registration Support
Real-world data generated in Lecheng may support later China registration discussions when evidence quality, study design, and regulatory requirements are met.
New Biomedical Technology Pilot
A regulated Lecheng pilot supports clinical research, translation, and application of selected new biomedical technologies under institutional qualification, technical and ethics review, and regulatory oversight.
Industrial Landing & Source-Based Guidance
We use official sources to assess relevant institutions, implementation requirements, and landing options across Lecheng and other Hainan healthcare and life-science clusters.
PATHWAY COMPARISON
Boao Lecheng & Greater Bay Area
1
Hainan pathway
Boao Lecheng International Medical Tourism Pilot Zone
A special medical zone focused on controlled clinical use of clinically urgent imported drugs and medical devices, international medical services, and real-world data pathways.
- Best fit: overseas-approved innovative drugs or devices that are not yet approved in mainland China and have a clear clinical urgency scenario.
- Access model: use is channelled through qualified Lecheng medical institutions, with import, use, monitoring, and traceability handled under special procedures.
- Regulatory value: real-world data generated in Lecheng may support later China registration communication for selected products, subject to evidence quality and regulator review.
- Policy support: eligible Lecheng institutions, medical education bodies, and research institutes may benefit from zero-tariff treatment for listed imported drugs and medical devices before Hainan island-wide customs closure.
2
GBA pathway
Greater Bay Area Hong Kong-Macao Drug and Device Connect
A cross-border clinical-use mechanism for the nine mainland GBA cities, linking Hong Kong and Macao approved or used products with designated mainland medical institutions.
- Best fit: products already registered in Hong Kong or Macao, or medical devices already procured and used by Hong Kong or Macao public hospitals, where there is urgent clinical need in mainland GBA institutions.
- Access model: designated medical institutions in the nine mainland GBA cities apply to import and use eligible catalogue or non-catalogue products under Guangdong procedures.
- Current scale: the 2025 catalogue includes 115 products, covering 45 drugs and 70 medical devices, while broader official reporting indicates approved use has continued to expand across designated institutions.
- Strategic value: useful for companies with Hong Kong or Macao access first, or for clinical adoption strategies built around GBA hospital networks and cross-border healthcare demand.
| Comparison point | Boao Lecheng | Greater Bay Area |
|---|---|---|
| Core policy logic | Hainan special-zone access for overseas-approved, mainland China-unapproved clinically urgent products. | Cross-border GBA access for Hong Kong/Macao drugs and devices used through designated mainland GBA hospitals. |
| Best company fit | Innovators seeking China-entry evidence, Lecheng clinical use, RWD potential, and Hainan FTP policy positioning. | Innovators with Hong Kong/Macao registration or hospital-use footprint who want GBA clinical adoption. |
| Where use happens | Qualified medical institutions in Boao Lecheng, Hainan. | Designated medical institutions across the nine mainland cities of the Guangdong-Hong Kong-Macao Greater Bay Area. |
| Evidence and registration value | Lecheng RWD may be positioned for later China registration discussions when data quality and regulatory requirements are met. | GBA use can support clinical familiarity and cross-border adoption; registration value depends on product pathway and regulator engagement. |
| Commercial boundary | Controlled special access; not the same as full mainland China marketing approval. | Controlled designated-institution use; not the same as nationwide mainland China distribution approval. |
START HERE
Start Your Pathway Assessment
ABOUT HAINAN
Hainan as a Healthcare Access Zone
ABOUT ASTERNEXIS ADVISORY
Connecting Innovation to China Healthcare
WHY ASTERNEXIS ADVISORY
Why Work With Us
AsterNexis Advisory is positioned as a cautious, source-based advisory platform for overseas healthcare teams evaluating China special-access options.
China Healthcare Policy Research
We organize policy information into practical market-entry questions for overseas teams.
Hainan and Lecheng Tracking
We monitor Hainan Free Trade Port and Boao Lecheng pathway relevance for healthcare products.
China-Based Resource Mapping
We help identify relevant clinical, industrial, park, commercial, and investment resources.
Plain-English Reports
We translate policy and pathway complexity for overseas executive, regulatory, and commercial teams.
Cautious Positioning
We do not present special access as a shortcut, guarantee, or replacement for official review.